EBS
Price
$6.23
Change
+$0.36 (+6.13%)
Updated
Sep 11 closing price
Capitalization
319.43M
60 days until earnings call
Intraday BUY SELL Signals
INEQ
Price
$41.92
Change
+$0.54 (+1.30%)
Updated
Sep 11 closing price
Net Assets
104.23M
Intraday BUY SELL Signals
Interact to see
Advertisement

EBS vs INEQ

EBS vs INEQ Comparison Chart in %
View a ticker or compare two or three
VS
EBS vs. INEQ commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and INEQ is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EBS: Fundamental Ratings
EBS
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EBSINEQ
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 3 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
COMPARISON
Comparison
Sep 13, 2026
Stock price -- (EBS: $6.23)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green while .

  • EBS’s FA Score: 1 green, 4 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 4 TA indicator(s) are bullish.

  • EBS’s TA Score: 4 bullish, 4 bearish.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а +0.32% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -5.31%. For the same industry, the average monthly price growth was -4.84%, and the average quarterly price growth was +30.17%.

Reported Earning Dates

EBS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-5.31% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
EBS
Daily Signal:
Gain/Loss:
INEQ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LINYX25.33N/A
N/A
Lord Abbett International Opp I
HWAIX46.70N/A
N/A
Hotchkis & Wiley Opps Instl
VETAX50.30N/A
N/A
Victory Sycamore Established Value A
TEQIX17.20N/A
N/A
Franklin Mutual Quest A
ABLOX24.92N/A
N/A
Alger Balanced I-2

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+6.13%
SIGA - EBS
40%
Loosely correlated
+0.33%
AMPH - EBS
39%
Loosely correlated
+1.02%
COLL - EBS
36%
Loosely correlated
-0.74%
XERS - EBS
33%
Loosely correlated
-2.87%
VTRS - EBS
30%
Poorly correlated
+0.79%
More

INEQ and

Correlation & Price change

A.I.dvisor tells us that INEQ and AMP have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INEQ and AMP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INEQ
1D Price
Change %
INEQ100%
+1.30%
AMP - INEQ
25%
Poorly correlated
+0.74%
SHEL - INEQ
17%
Poorly correlated
+0.84%
MRK - INEQ
16%
Poorly correlated
-0.54%
CON - INEQ
16%
Poorly correlated
+2.07%
EBS - INEQ
11%
Poorly correlated
+6.13%
More